PUBLISHER: GlobalData | PRODUCT CODE: 1213695
PUBLISHER: GlobalData | PRODUCT CODE: 1213695
This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late- clinical stage pipeline products, with a launch date assessment by market for Acute lymphocytic leukemia (ALL). This report also contains a sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 major markets (15MM). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and PharmOnline International (POLI) Price Intelligence databases.
The report also analyzes the clinical and commercial landscapes of ALL, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied by a transparent forecast methodology. Additionally, the report evaluates indication-specific unmet needs and competitive assessments and identifies key future players in the cell therapy market.
Cell therapies face a high level of competition in ALL. Gene-modified cell therapies are expected to face significant competition from antibody-based therapies, which have demonstrated promising efficacy in the relapsed/refractory (R/R) settings and have a price advantage over chimeric antigen receptor T-cells (CAR-Ts).
Pipeline CAR-Ts will likely require a novel target, increased efficacy, lower price, or simplified manufacture to penetrate the crowded CAR-T market.
Forecast includes 8 countries
Forecast covers 2021-2031
Seven markets are extrapolated, obtaining a 15-market value for all ALL therapeutics
Our indication specific forecast models answer questions such as -